Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Frequently Asked Questions on COVID-19 in Special Populations and Patients With Comorbidities

Vikramjit Mukherjee, MD
Paul E. Sax, MD
Lynora Saxinger, MD, FRCPC, CTropMed
Dr Wong Chen Seong
Released: July 8, 2020
Back Next

References

Alqahatani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity, and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15:e0233147.

Blanco J, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7:e314-e316.

Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 Patients hospitalized in the United States. J Diabetes Sci Technol. 2020;14:813-821.

Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2020;[Epub ahead of print].

British HIV Association. BHIVA interim ART guidelines COVID-19 v2 07082020. Available at: https://www.bhiva.org/file/5f56057450cc3/BHIVA-interim-ART-guidelines-COVID-19.pdf. Accessed November 13, 2020.

ClinicalTrials.gov. Randomized clinical trial for the prevention of SARS-CoV-2 infection (COVID-19) in healthcare personnel (EPICOS). Available at: https://clinicaltrials.gov/ct2/show/NCT04334928. Accessed November 13, 2020.

ClinicalTrials.gov. The coronavirus disease 2019 angiotensin converting enzyme inhibitor/angiotensin receptor blocker investigation (CORONACION) randomized clinical trial. Available at: https://clinicaltrials.gov/ct2/show/NCT04330300. Accessed November 13, 2020.

del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. Ann Intern Med. 2020;Jun 26:M20-3689.

Elfiky A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020;253:117592.

Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648-654.

Mirzaei J, MeFarland W, Karamouzian M, et al. COVID-19 among people living with HIV: a systematic review. AIDS Behav. 2020:1-8.

Park LS. COVID-19 in the largest US HIV cohort. Program and abstracts of the 23rd International AIDS Conference Virtual (AIDS 2020); July 6-10, 2020. Abstract LBPEC23.

Qui H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20:689-696.

Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID-19 patients: Implications and guidance for the management of blood glucose in people with and without diabetes. Diabet Med. 2020:e14378.

Sigel K, Swartz T, Golden E, et al. Covid-19 and people with HIV infection: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;[Epub ahead of print].

Simon D, Tascilar K, Krönke G, et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020;11:3774.

Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.

Zrzavy T, Wimmer I, Rommer PS, et al. Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. Eur J Neurol. 2020;[Epub ahead of print].

Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue